ZLD Stock Overview
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.71 |
| 52 Week High | AU$3.35 |
| 52 Week Low | AU$0.68 |
| Beta | 0.52 |
| 1 Month Change | 1.43% |
| 3 Month Change | -18.39% |
| 1 Year Change | -21.98% |
| 3 Year Change | -93.00% |
| 5 Year Change | -90.98% |
| Change since IPO | -82.36% |
Recent News & Updates
Recent updates
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 08
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Jul 14Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely
Jan 19Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Sep 25Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Jun 03A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Dec 31
Shareholder Returns
| ZLD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 2.9% | -3.0% | -2.2% |
| 1Y | -22.0% | 37.1% | 4.5% |
Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned 37.1% over the past year.
Return vs Market: ZLD underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| ZLD volatility | |
|---|---|
| ZLD Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ZLD's share price has been volatile over the past 3 months.
Volatility Over Time: ZLD's weekly volatility has decreased from 34% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| ZLD fundamental statistics | |
|---|---|
| Market cap | AU$8.17m |
| Earnings (TTM) | -AU$36.43m |
| Revenue (TTM) | AU$278.90k |
28.9x
P/S Ratio-0.2x
P/E RatioIs ZLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZLD income statement (TTM) | |
|---|---|
| Revenue | AU$278.90k |
| Cost of Revenue | AU$358.24k |
| Gross Profit | -AU$79.34k |
| Other Expenses | AU$36.35m |
| Earnings | -AU$36.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.21 |
| Gross Margin | -28.45% |
| Net Profit Margin | -13,062.44% |
| Debt/Equity Ratio | -68.8% |
How did ZLD perform over the long term?
See historical performance and comparison